Case 31. bNAbs – Will They Be Broadly Used?
Download MP3A patient asks, “Can I get the every-six-month treatment?” Listen as Eileen Scully and Chris Hoffmann of Johns Hopkins review recent study results on HIV treatment with lenacapavir and two broadly neutralizing antibodies (bNAbs), the status of bNAbs for HIV treatment, cure, and prevention, and what to discuss with patients considering a bNAb clinical trial.
References:
References:
- Balazs, A., Chen, J., Hong, C, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012:481, 81–84. PMID: 22139420
- Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021 Mar 18;384(11):1003-1014. doi: 10.1056/NEJMoa2031738. PMID: 33730454
- Lee M, Cherrill L, Zacharopoulou P, et al. Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial. Lancet HIV 2026; 13: e527-e537. PMID: 42202839
- McMahon J, Eron J, Gaur A, et al. Efficacy and safety of twice-yearly lenacapavir, teropavimab and zinlirvimab as an HIV-1 Treatment for up to 104 Weeks. JIAS. Volume 29, Issue S4 Supplement: Abstracts from AIDS 2026, the 26th International AIDS Conference, 26–31 July 2026 Rio de Janeiro, Brazil and virtual July 2026. OAB1403
- Ndung'u T, Dong KL, Colby DJ, et al. Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research trials. Lancet HIV 2026 Apr;13(4):e271-e281. PMID: 41747748
